Remedium Lifecare Ltd (REMLIFE) is currently trading at 0.26 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Remedium Lifecare Limited is a pharmaceutical company specializing in trading and selling APIs and intermediates. They operate in both domestic and international markets, including regulated ones. The company changed its name from 'Roxy Exports Limited' to 'Remedium Lifecare Limited' to reflect its updated business focus. In 2021, Remedium Lifecare transitioned from manufacturing Air-O-Water machines to trading API intermediates and contract manufacturing, indicating a strategic realignment. Remedium Lifecare emphasizes innovation in the pharmaceutical industry, focusing on trading advanced intermediates vital for API manufacturing. Its history dates back to 1988, positioning it as an experienced entity in the evolving pharmaceutical sector.

Over the past 52 weeks, Remedium Lifecare Ltd has traded between a low of ₹0.25 and a high of ₹1.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Remedium Lifecare Ltd has a market capitalization of approximately 22.93. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Remedium Lifecare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -10.52 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 22.93 Cr, Remedium Lifecare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Remedium Lifecare Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Remedium Lifecare Ltd is -10.52. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The company disclosed that MCA approved the name change from Remedium Lifecare Ltd. to Supha Pharmachem Limited, effective 15/12/2025.

Supha Pharmachem, formerly Remedium Lifecare, was admitted into the Corporate Insolvency Resolution Process (CIRP) by the NCLT after it defaulted on a payment of ₹7.47 crore to an operational creditor, Boston Ivy Healthcare Solution Private Limited.

Supha Pharmachem entered the Corporate Insolvency Resolution Process (CIRP) after the NCLT admitted a petition from Boston Ivy Healthcare Solution Private Limited due to a payment default of Rs. 7,47,20,079.

The most significant announcement is the 'Biopharma Shakti' initiative, a ₹10,000 crore program designed to boost domestic manufacturing of biologics and biosimilars, which is expected to increase demand for API intermediates traded by the company.